MacuCLEAR, Inc. completed a successful Phase Ib / POC Human Clinical Trial. The results of this trial demonstrated MC-1101 was safe and well tolerated by all study patients. In addition, laser doppler measurements proved 1) MacuCLEAR’s drug reaches the back of the eye, and 2) when it gets there, has a biological effect on choroidal blood flow.
This Graph shows MC-1101’s positive effect on modulating Choroidal Blood Flow (CBF) in Humans. CBF has been linked to the etiology of AMD by several researchers.
Additional preclinical data regarding MC-1101’s effect on inflammation and oxidative stress can be made available under appropriate confidential non-disclosure agreements.